Pfizer Pharmaceuticals Korea’s ‘Xalkori’ extended in insurance benefit from this January

Pfizer Pharmaceuticals Korea(CEO/President Dong-Wook Oh) announced its targeted therapy for lung cancer, ‘Xalkori(generic name: crizotinib),’ will be applied by the health insurance benefit as a primary treatment of anaplastic lymphoma kinase(ALK)-positive local-progressive or metastatic non-small cell lung cancer patients from January 2017 in accordance with the Health Insurance Review & Asses...